These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Melief CJ; Van Der Burg SH; Toes RE; Ossendorp F; Offringa R Immunol Rev; 2002 Oct; 188():177-82. PubMed ID: 12445291 [TBL] [Abstract][Full Text] [Related]
6. Tumor cells endowed with professional antigen-presenting cell functions prime PBLs to generate antitumor CTLs. Chiozzini C; Olivetta E; Sanchez M; Arenaccio C; Ferrantelli F; Leone P; Federico M J Mol Med (Berl); 2019 Aug; 97(8):1139-1153. PubMed ID: 31161312 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic vaccination with tumor cells that engage CD137. Hellstrom KE; Hellstrom I J Mol Med (Berl); 2003 Feb; 81(2):71-86. PubMed ID: 12601523 [TBL] [Abstract][Full Text] [Related]
8. Specific immunotherapy of cancer in elderly patients. Matzku S; Zöller M Drugs Aging; 2001; 18(9):639-64. PubMed ID: 11599633 [TBL] [Abstract][Full Text] [Related]
9. Ex vivo-activated MHC-unrestricted immune effectors for cancer adoptive immunotherapy. Leuci V; Mesiano G; Gammaitoni L; Todorovic M; Giraudo L; Carnevale-Schianca F; Aglietta M; Sangiolo D Anticancer Agents Med Chem; 2014 Feb; 14(2):211-22. PubMed ID: 24237224 [TBL] [Abstract][Full Text] [Related]
10. [Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy]. Benchetrit F; Gazagne A; Adotevi O; Haicheur N; Godard B; Badoual C; Fridman WH; Tartour E Bull Cancer; 2003; 90(8-9):677-85. PubMed ID: 14609756 [TBL] [Abstract][Full Text] [Related]
11. Immunotherapy II: Antigens, receptors and costimulation. Searle PF; Young LS Cancer Metastasis Rev; 1996 Sep; 15(3):329-49. PubMed ID: 9034595 [TBL] [Abstract][Full Text] [Related]
12. T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance. Cohen PA; Peng L; Kjaergaard J; Plautz GE; Finke JH; Koski GK; Czerniecki BJ; Shu S Crit Rev Immunol; 2001; 21(1-3):215-48. PubMed ID: 11642606 [TBL] [Abstract][Full Text] [Related]
13. Tumor cell lysates as immunogenic sources for cancer vaccine design. González FE; Gleisner A; Falcón-Beas F; Osorio F; López MN; Salazar-Onfray F Hum Vaccin Immunother; 2014; 10(11):3261-9. PubMed ID: 25625929 [TBL] [Abstract][Full Text] [Related]
14. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Bodey B; Bodey B; Siegel SE; Kaiser HE Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341 [TBL] [Abstract][Full Text] [Related]
15. Impairment of T-cell activation in head and neck cancer in situ and in vitro: strategies for an immune restoration. Lang S; Whiteside TL; Lebeau A; Zeidler R; Mack B; Wollenberg B Arch Otolaryngol Head Neck Surg; 1999 Jan; 125(1):82-8. PubMed ID: 9932594 [TBL] [Abstract][Full Text] [Related]
16. [Antitumor immunity and cellular cancer therapies]. Catros-Quemener V; Bouet F; Genetet N Med Sci (Paris); 2003 Jan; 19(1):43-53. PubMed ID: 12836191 [TBL] [Abstract][Full Text] [Related]
17. B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes. Johnston JV; Malacko AR; Mizuno MT; McGowan P; Hellström I; Hellström KE; Marquardt H; Chen L J Exp Med; 1996 Mar; 183(3):791-800. PubMed ID: 8642283 [TBL] [Abstract][Full Text] [Related]
18. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy. da Cunha A; Antoniazi Michelin M; Cândido Murta EF Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825 [TBL] [Abstract][Full Text] [Related]